Search Medical Condition
Please enter condition
Please choose location from dropdown

Oslo, Norway Clinical Trials

A listing of Oslo, Norway clinical trials actively recruiting patients volunteers.

RESULTS

Found (371) clinical trials

Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

Breast cancer is rarely curable after metastasis, and the therapeutic options for metastatic triple negative breast cancer (TNBC) are limited. The host immune response is strongly predictive for the effect of chemotherapy in patients with TNBC. In the present trial, we combine Atezolizumab, an inhibitory antibody against Programmed Death Ligand-1 ...

Phase

0.0 miles

Learn More »

nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis

This is a two-phase multicenter, double-blind, randomized, prospective evaluation of intra-articular injection(s) comparing APS to intra-articular HA injection(s). The maximum study duration for each subject will be 62 months; 60 months from treatment to last follow-up, and two additional months if the maximum visit window is realized. A total of ...

Phase N/A

0.0 miles

Learn More »

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in up to 48 patients with previously treated advanced adenocarcinoma of the lung. The study will utilise an extension of Simon's 2-stage design. The primary ...

Phase

0.0 miles

Learn More »

A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis

The purpose of this study is to monitor the long-term safety of ustekinumab in pediatric participants (aged greater than or equal to 12 years to less than 18 years inclusive) with moderate to severe plaque psoriasis, through monitoring for the following adverse events potentially related to immune modulation: serious infections, ...

Phase N/A

0.0 miles

Learn More »

Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase

Pegylated-asparaginase (PEG-ASP) is an important part of the treatment of childhood acute lymphoblastic leukaemia (ALL). Unfortunately 13% of patients develops allergy and further treatment is impossible. Furthermore, 6% of patients have developed antibodies (silent inactivation) and have no effect of the PEG-ASP treatment. Truncated asparaginase therapy is associated with inferior ...

Phase

0.0 miles

Learn More »

Global Anticoagulant Registry in the Field

Using data from more than 1000 randomly selected centres across 35 countries, representing all possible care settings, the registry will help to characterize real-life anticoagulant treatment patterns and outcomes, including rates of stroke and bleeding complications, as well as provide data on other important issues, such as physicians' compliance with ...

Phase N/A

0.0 miles

Learn More »

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in the PDGFRA gene. Approximately 120 subjects will be randomized in a 2:1 ratio to receive either crenolanib 100 ...

Phase

0.0 miles

Learn More »

REU-stop - Effect of Intensive Smoking Cessation Intervention on Smoking Cessation and Disease Activity in Patients With Rheumatoid Arthritis.

Tobacco smoking is a well-known environmental risk factor for developing rheumatoid arthritis (RA). The onset of RA can occur in all age groups, with the majority being women aged 50-60 years. RA is a chronic inflammatory disease and cannot be cured. However, the activity of the disease can be reduced ...

Phase N/A

0.0 miles

Learn More »

Non-interventional Post-authorisation Study to Document the Immunogenicity Safety and Efficacy of NUWIQ

Prospective, multinational, non-interventional post-authorisation study to collect additional clinical data and to ensure consistency in the long-term between the outcome from pre-authorisation clinical studies (in 135 previously treated paediatric and adult patients) and routine clinical practice. Besides aspects such as general product safety and efficacy, there will be a focus ...

Phase N/A

0.0 miles

Learn More »

Prospective Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

The purpose of the study is to evaluate the effectiveness of Elocta compared to conventional factor products in the prophylactic treatment of patients with haemophilia A over a 24-month prospective period. Data will also be collected for a 12 month retrospective period.

Phase N/A

0.0 miles

Learn More »